Zai Lab Limited

NASDAQ:ZLAB

Biotechnology

Healthcare
$22.11 +3.42%

+$0.61 today

Market cap
$2.49B
Beta
0.78
P/E (TTM)
-11.4
EPS (TTM)
-$0.16
52W Low $15.96High $41.20

Volume 1.04M

Average 0.87M

ZLAB Debt Repayment

Cash used to repay borrowings during the period.

Zai Lab LimitedNASDAQ: ZLAB

Debt Repayment · Q2 FY2026 · quarter ended Jun 2026

Debt repayment growth accelerates

Q2 FY2026 debt repayment of $19.96M rose 2984.7% year over year, ahead of the -47.9% change in trailing-twelve-month debt repayment. Sequentially, it rose 184.8% from the prior quarter.

Context

  • Debt repayment amounted to 14.8% of revenue in FY2025, down 18.1 pp from a year earlier.
  • Debt repayment increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth of +2984.7% holds above the trailing-twelve-month pace of -47.9%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
$19.96M+184.8% QoQ
Last fiscal yearDec 2025
$67.94M-48.3% YoY
LTMJun 2026
$53.38M-47.9% YoY
Debt Repayment past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+2984.7%——
1 year-48.3%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Debt Repayment history

USD · from the cash flow

Latest · FY2025
67.94M USD
Year-over-year change
-48.3%

Debt Repayment vs competitors

How ZLAB compares with its peers on the latest reported figures

  • Peers report in different currencies, so debt repayment is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -47.9% is the lowest of 2, against a peer median of +311.4%.
  • Debt repayment amounts to 11.9% of revenue for ZLAB, versus a peer median of 0.0%.
ZLAB Competitors
Debt Repayment for ZLAB and competitors
Company Period LTM YoY 3-year CAGR% of revenue
AAPGAscentage Pharma Group InternationalFY2025CN¥307.26M CNY+311.4%-23.9%55.0%
ZLABZai Lab LimitedLTM Jun 2026$53.38M USD-47.9%—11.9%
HCMHUTCHMED (China) LimitedLTM Jun 2025$0 USD——0.0%
ANLAdlai Nortye Ltd.LTM Jun 2024$0 USD—-32.3%0.0%
Peer median (excluding ZLAB) —+311.4%-28.1%0.0%

Competitors are the stored peer set for ZLAB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(704.47M)(443.29M)(334.62M)(257.1M)(175.54M)
Depreciation & Amortization6.49M8.23M9.03M11.86M15.01M
Deferred Income Tax17.08M0000
Stock-Based Compensation40.71M61.3M79.63M70.65M65.6M
Change in Working Capital23.11M(66.25M)39.61M(68.39M)(54.71M)
Accounts Receivables(42.32M)25.14M(17.69M)(26.58M)(29.98M)
Inventory(7.17M)(15.38M)(14.91M)3.9M(47.03M)
Accounts Payables63.52M(53.77M)36.8M(2.21M)19.93M
Other Working Capital9.08M(22.23M)35.4M(43.5M)2.38M
Other Non-Cash Items67.85M72.36M8.17M28.12M(1.15M)
Operating Cash Flow(549.23M)(367.64M)(198.18M)(214.87M)(150.79M)
Capital Expenditures(18.95M)(24.98M)(8.49M)(61.52M)(13.42M)
Acquisitions (Net)(30M)0029K0
Purchases of Investments(445M)(260.27M)(134M)(330M)(10M)
Sales of Investments743.9M705.27M117.7M16.3M331.2M
Other Investing Activities3K(399K)12.74M(55.86M)(5.24M)
Investing Cash Flow249.96M420.02M(10.78M)(375.19M)307.87M
Debt Repayment000131.32M67.94M
Common Stock Issued818.88M00217.35M13.68M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities1.33M(1.73M)(6.43M)1.22M(9.27M)
Financing Cash Flow820.2M(1.73M)(6.43M)349.89M72.35M
Effect of Forex Changes1.12M(6.27M)(2.62M)(310K)478K
Net Change in Cash522.04M44.37M(218.01M)(240.48M)229.91M
Free Cash Flow(568.18M)(392.63M)(206.67M)(276.39M)(164.21M)

Zai Lab Limited

NASDAQ:ZLAB

Intrinsic Alpha fair value

Locked

Current Price

$22.11

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.